About Zinc finger protein 626
Zinc finger protein 626 (ZNF626) is a protein
from Homo sapiens identified by UniProt accession
Q68DY1, 528 residues long.
MolForge cross-references it against 0 known binders and
10 disease associations.
Target properties
| Protein name | Zinc finger protein 626 |
| UniProt accession | Q68DY1 |
| Gene | ZNF626 |
| Organism | Homo sapiens |
| Length | 528 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (10)
Diseases linked to this target (Open Targets).
- nasopharyngeal neoplasm · score 0.37
- pancreatic adenocarcinoma · score 0.14
- Down syndrome · score 0.05
- endometrial carcinoma · score 0.02
- chronic interstitial cystitis · score 0.01
- breast cancer · score 0.01
- bipolar disorder · score 0.01
- hypertrophic cardiomyopathy · score 0.01
- squamous cell carcinoma · score 0.00
- post-traumatic stress disorder · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q68DY1-F1 | alphafold | PREDICTED | 71.52 | — |
Amino-acid sequence (528 residues)
MGPLQFRDVA IEFSLEEWHC LDTAQRNLYR NVMLENYSNL VFLGITVSKP DLITCLEQGR KPLTMKRNEM IAKPSVMCSH FAQDLWPEQS MKDSFQKVVL RRYEKCEHDN LQLKKGCISV DECKVHKEGY NELNQCLTTT PRKICQCDKY VKVLHQFPNS NGQKRGHTGK KPFKYIECGK AFKQFSTLTT HKKIHTGGKP YKCEECGKAF NHSCSLTRHK KIHTGEKPYK CEECGKAFKH SSTLTTHKRN HTGEKPYKCD KCGKAFMSSS TLSKHEIIHT EKKPYKCEEC GKAFNRSSTL TTHKIIHTGE KPYKCEECDK AFKYSYTLTT HKRIHTEDKP YKCEECGKAF KYSSTLTTHK RIHTGEKPYK CEECGKAFKR SSDLTTHKII HTGEKPYKCE ECGKAFKYSS NLTTHKKIHT GERPYKCEEC GKAFNQSSIL TTHRRIHTGE KFYKCEECGK AFKCSSNLTT HKKIHTGERP YKCEECGKAF NQSSILTTHE RIILERNSTN VKNVAKPSSG PHTLLHIR
Explore Zinc finger protein 626 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets